 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...36373839404142434445464748» |
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: SALTER: S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=52, Not yet recruiting, Sponsor: Taizhou Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ALTER-S005: Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients (clinicaltrials.gov) - Jan 24, 2019
P2, N=47, Not yet recruiting, Sponsor: Liaoning Tumor Hospital & Institute
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date, Combination therapy, Metastases: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) (clinicaltrials.gov) - Jan 23, 2019
P2, N=80, Recruiting, Sponsor: Shenzhen People's Hospital
Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> May 2018
- | Ximotini (simotinib) / Simcere, Advenchen
New P1 trial, Metastases: Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC (clinicaltrials.gov) - Jan 19, 2019
P1, N=30, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- ||| Conmana (icotinib) / Betta Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: ALTER-L004: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (clinicaltrials.gov) - Jan 17, 2019
P2, N=58, Enrolling by invitation, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> May 2018 Not yet recruiting --> Enrolling by invitation
- | New P1/2 trial, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker: FUSCC Refractory TNBC Umbrella (FUTURE) (clinicaltrials.gov) - Jan 15, 2019
P1/2, N=140, Recruiting, Sponsor: Fudan University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial: ALTER-L013: Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (clinicaltrials.gov) - Jan 9, 2019
P4, N=45, Not yet recruiting, Sponsor: Tongji Hospital
- ||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Metastases: Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC (clinicaltrials.gov) - Jan 9, 2019
P=N/A, N=20, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin (clinicaltrials.gov) - Jan 3, 2019
P2, N=62, Not yet recruiting, Sponsor: Lingyu Luo
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ALTER-S003: Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy (clinicaltrials.gov) - Jan 3, 2019
P2, N=44, Not yet recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, Metastases: ALTER L012: Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC (clinicaltrials.gov) - Dec 31, 2018
P1, N=43, Recruiting, Sponsor: Henan Cancer Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - Dec 20, 2018
P2, N=116, Not yet recruiting, Sponsor: Third Military Medical University
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ALTER-L025: Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (clinicaltrials.gov) - Dec 19, 2018
P2, N=51, Recruiting, Sponsor: Henan Provincial Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial, Metastases: Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006) (clinicaltrials.gov) - Dec 19, 2018
P4, N=72, Not yet recruiting, Sponsor: LanZhou University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC (clinicaltrials.gov) - Dec 19, 2018
P2, N=30, Not yet recruiting, Sponsor: First Hospital of Shijiazhuang City
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: CSOAIMTOAN: Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC (clinicaltrials.gov) - Dec 9, 2018
P=N/A, N=83, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Conmana (icotinib) / Betta Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase classification, Metastases: ALTER-L004: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (clinicaltrials.gov) - Dec 8, 2018
P2, N=58, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P2
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial, Metastases: Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC (clinicaltrials.gov) - Dec 7, 2018
P4, N=106, Recruiting, Sponsor: Guangdong Association of Clinical Trials
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 6, 2018
P=N/A, N=66, Not yet recruiting, Sponsor: The First Affiliated Hospital of Soochow University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: AHCTAHCOSAECT: Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Dec 6, 2018
P=N/A, N=40, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative (clinicaltrials.gov) - Dec 4, 2018
P2, N=20, Recruiting, Sponsor: First Hospital of Shijiazhuang City
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Combination therapy, Metastases: ALTER-L024: A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (clinicaltrials.gov) - Nov 28, 2018
P2, N=80, Recruiting, Sponsor: China Medical University, China
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial: Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line?ALTER-L020? (clinicaltrials.gov) - Nov 28, 2018
P4, N=103, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ACDFNSNSCLC: Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 22, 2018
P2, N=46, Not yet recruiting, Sponsor: Qilu Hospital of Shandong University
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Biomarker, New trial: Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) (clinicaltrials.gov) - Nov 16, 2018
P=N/A, N=40, Recruiting, Sponsor: Shenzhen People's Hospital
- | docetaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: PROACH: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (clinicaltrials.gov) - Nov 15, 2018
P2, N=188, Not yet recruiting, Sponsor: Ruijin Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial: Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer?ALTER-L029? (clinicaltrials.gov) - Nov 15, 2018
P4, N=90, Not yet recruiting, Sponsor: Anhui Shi, MD
- | Conmana (icotinib) / Betta Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, New trial, Metastases: ALTER-L004: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (clinicaltrials.gov) - Nov 9, 2018
P=N/A, N=58, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ACDFNSCLC: Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer?ALTER-L034? (clinicaltrials.gov) - Nov 8, 2018
P2, N=46, Not yet recruiting, Sponsor: The Affiliated Hospital of Qingdao University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib in Treatment of Recurrent Small Cell Lung Cancer (clinicaltrials.gov) - Nov 7, 2018
P2, N=43, Recruiting, Sponsor: Beijing Cancer Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: ALTER-L024: A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (clinicaltrials.gov) - Nov 5, 2018
P2, N=80, Not yet recruiting, Sponsor: China Medical University, China
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma (clinicaltrials.gov) - Nov 2, 2018
P2, N=38, Not yet recruiting, Sponsor: First Affiliated Hospital of Wenzhou Medical University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: ACWDVDFPTAN: Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (clinicaltrials.gov) - Oct 30, 2018
P1/2, N=97, Not yet recruiting, Sponsor: Yong Fang
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: secgolc004: EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC (clinicaltrials.gov) - Oct 24, 2018
P2, N=90, Recruiting, Sponsor: Fujian Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells (clinicaltrials.gov) - Oct 23, 2018
P2, N=36, Not yet recruiting, Sponsor: Hebei Medical University
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: Y-HR2017-025: Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies (clinicaltrials.gov) - Oct 18, 2018
P1/2, N=30, Recruiting, Sponsor: China International Medical Foundation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC (clinicaltrials.gov) - Oct 14, 2018
P2, N=62, Not yet recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC (clinicaltrials.gov) - Oct 12, 2018
P2, N=88, Not yet recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Trial initiation date, Trial primary completion date, Metastases: A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (clinicaltrials.gov) - Oct 9, 2018
P2, N=38, Active, not recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Initiation date: May 2017 --> Dec 2016 | Trial primary completion date: Oct 2018 --> Jul 2018
- | lobaplatin (D19466) / AEterna Zentaris, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC (clinicaltrials.gov) - Oct 9, 2018
P2, N=60, Not yet recruiting, Sponsor: The First Affiliated Hospital of Guangzhou Medical University
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Phase classification, Trial completion date, Trial primary completion date, Metastases: ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 19, 2018
P2, N=30, Not yet recruiting, Sponsor: Changzhou No.2 People's Hospital
Recruiting --> Active, not recruiting | Initiation date: May 2017 --> Dec 2016 | Trial primary completion date: Oct 2018 --> Jul 2018 Phase classification: P3 --> P2 | Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 18, 2018
P1/2, N=40, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Phase classification: P3 --> P2 | Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Phase classification, Metastases: ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 18, 2018
P3, N=30, Not yet recruiting, Sponsor: Changzhou No.2 People's Hospital
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P3
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, New P3 trial, Metastases: ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 18, 2018
P3, N=30, Not yet recruiting, Sponsor: Changzhou No.2 People's Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Metastases: Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC (clinicaltrials.gov) - Sep 14, 2018
P=N/A, N=20, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients (clinicaltrials.gov) - Sep 13, 2018
P2, N=25, Not yet recruiting, Sponsor: Shandong Cancer Hospital and Institute
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial withdrawal, Metastases: ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 12, 2018
P=N/A, N=0, Withdrawn, Sponsor: Changzhou No.2 People's Hospital
Phase classification: P=N/A --> P3 Not yet recruiting --> Withdrawn | N=30 --> 0
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 11, 2018
P3, N=336, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Withdrawn | N=30 --> 0 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial primary completion date, Metastases: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Sep 5, 2018
P2, N=43, Active, not recruiting, Sponsor: Peking University People's Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Sep 2018
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC (clinicaltrials.gov) - Aug 31, 2018
P2, N=84, Not yet recruiting, Sponsor: First Affiliated Hospital of Guangxi Medical University